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Abstract
Background: Despite quick implementation of reperfusion therapies, a few patients with high-risk, acute, massive,
pulmonary embolism (PE) remain highly hemodynamically unstable. Others have absolute contraindication to
receive reperfusion therapies. Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) might lower their
right ventricular overload, improve hemodynamic status, and restore tissue oxygenation.
Methods: ECMO-related complications and 90-day mortality were analyzed for 17 highly unstable, ECMO-treated,
massive PE patients admitted to a tertiary-care center (2006–2015). Hospital- discharge survivors were assessed for
long-term health-related quality of life. A systematic review of this topic was also conducted.
Results: Seventeen high-risk PE patients [median age 51 (range 18–70) years, Simplified Acute Physiology Score II
(SAPS II) 78 (45–95)] were placed on VA-ECMO for 4 (1–12) days. Among 15 (82%) patients with pre-ECMO cardiac
arrest, seven (41%) were cannulated during cardiopulmonary resuscitation, and eight (47%) underwent pre-ECMO
thrombolysis. Pre-ECMO median blood pressure, pH, and blood lactate were, respectively: 42 (0–106) mmHg, 6.99
(6.54–7.37) and 13 (4–19) mmol/L. Ninety-day survival was 47%. Fifteen (88%) patients suffered in-ICU severe
hemorrhages with no impact on survival. Like other ECMO-treated patients, ours reported limitations of all physical
domains but preserved mental health 19 (4–69) months post-ICU discharge.
Conclusions: VA-ECMO could be a lifesaving rescue therapy for patients with high-risk, acute, massive PE when
thrombolytic therapy fails or the patient is too sick to benefit from surgical thrombectomy. Because heparin-induced
clot dissolution and spontaneous fibrinolysis allows ECMO weaning within several days, future studies should
investigate whether VA-ECMO should be the sole therapy or completed by additional mechanical clot-removal
therapies in this setting.
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Background
Acute, massive high-risk pulmonary embolism (PE) is
defined as an embolus sufficiently obstructing pulmon-
ary blood flow to cause right ventricular (RV) failure,
hypoxemia, and hemodynamic instability [1]. Although
the epidemiology of massive PE is difficult to determine,
it remains a significant cause of cardiovascular morbidity
and mortality worldwide, with overall in-hospital mortal-
ity rates ranging from 25% for patients with cardiogenic
shock to 65% for those requiring cardiopulmonary resus-
citation [1, 2]. The latest European guidelines enhance
the clinical classification, based on the estimated PE-re-
lated early mortality risk, defined by in-hospital or
30-day mortality, with high-risk PE being suspected
or confirmed in the presence of shock or persistent
arterial hypotension [3]. Treatment is based on bedside
hemodynamic and respiratory support, unfractionated
heparin infusion (UFH), and reperfusion therapy with sys-
temic thrombolytic agents (class IB), surgical pulmonary
embolectomy (class IC) or percutaneous catheter-directed
thromboaspiration or embolectomy (class IIaC) [3]. Be-
cause of contraindications or major clinical instability, a
few patients are not amenable to reperfusion therap-
ies or fail to improve after this treatment. For them,
venoarterial-extracorporeal membrane oxygenation
(VA-ECMO) is one of the most reliable and quickest
ways to decrease RV overload, improve RV function
and hemodynamic status, and restore tissue oxygen-
ation. Although ECMO is increasingly available and
mobile ECMO teams, if locally available, can assure
rapid deployment of this salvage therapy, ECMO data
in this context are limited [4–7]. We describe herein
our tertiary-care center’s experience with VA-ECMO–
treated patients with acute, massive, high-risk PE, and
report their short- and long-term outcomes.
Methods
Patients
We retrospectively analyzed the ECMO database of our
26-bed intensive care unit (ICU), to identify all the pa-
tients referred (June 2006–June 2015) with suspected or
confirmed high-risk PE, indicating VA-ECMO support.
PE was diagnosed using the diagnostic strategy tools of
the latest European Society of Cardiology guidelines [3].
VA-ECMO indications were: acute refractory cardiovas-
cular failure, defined as evidence of tissue hypoxia (e.g.,
extensive skin mottling or elevated blood lactate) con-
comitant with adequate intravascular volume status; se-
verely diminished RV or left ventricular ejection fraction
(RV/LVEF); low cardiac index (≤2.1 L/min/m2); sus-
tained hypotension despite high-dose catecholamine in-
fusion (epinephrine ≥1 γ/kg/min or dobutamine ≥20 γ/
kg/min + norepinephrine ≥1 γ/kg/min). ECMO exclusion
criteria were malignancies with fatal prognosis within
5 years or irreversible neurological pathologies and deci-
sions to limit therapeutic interventions.
VA-ECMO cannulas were surgically inserted by
trained cardiovascular surgeons with femoral–femoral
23 F to 29 F–15 F to 18 F cannula as previously de-
scribed [8–10]. An additional 7 F catheter was systemat-
ically inserted into the femoral artery to prevent leg
ischemia. For highly unstable patients, our institution’s
Mobile ECMO Unit traveled to primary-care hospitals
with a portable ECMO system, implanted the device at
beside in the ICU and transported the patient to our
center. When cannulation was done during surgical pul-
monary embolectomy, the inflow cannula was placed in
the right atrium (RA) and the outflow line in the main
pulmonary artery (PA). Pump speed was adjusted to ob-
tain blood flow of 2.5–3.5 L/min with intravenous UHF
administered to maintain the activated partial thrombo-
plastin time at two to three times control levels (see
Additional file 1 for details on ECMO management)..
Pre-ECMO data collection
At ICU admission, we collected the following information:
demographics (age, sex, body mass index), admission
disease-severity scores (severity of underlying conditions
according to the McCabe and Jackson [11] and Charlson
scores [12]); presence of venous-thromboembolic risk fac-
tors; Simplified Acute Physiology Score (SAPS) II [13] and
Sequential Organ Failure Assessment (SOFA) score [14]).
During the pre-ECMO period, the inotrope score, defined
as dobutamine dose (γ/kg/min) + [norepinephrine dose
(γ/kg/min) + epinephrine dose (γ/kg/min)] × 100 [15]; car-
diac arrest with its related “no-flow” and “low-flow” dura-
tions; blood gas analyses, and troponin Ic were noted. The
following Doppler echocardiography variables were always
recorded: RV/LV dimension ratio, LVEF, and visualization
of a PA thrombus, before ECMO insertion. Similarly,
proximal PE and pulmonary infarction on chest computed
tomography (CT) scans were recorded. Lastly, pre-ECMO
reperfusion therapies (including thrombolysis, surgical
thrombectomy or percutaneous catheter-directed throm-
boaspiration or embolectomy), ECMO-related complica-
tions, and post-ECMO information were collected.
Outcome variables
The main outcome variables included ECMO weaning,
survival to hospital discharge, 90-day survival, and long-
term survival (evaluated in September 2015). We also
calculated each patient’s SOFA scores at cannulation and
days 1, 3, and 7; the inotrope score 24 hours post-
cannulation; ECMO and mechanical ventilation durations.
Lastly, in-ICU complications, e.g., severe hemorrhage, ar-
terial ischemia, surgical wound infection, stroke, and renal
replacement therapy requirement, were recorded. Bleeding
complications were reported using the Global Utilization
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of Streptokinase and TPA for Occluded arteries (GUSTO)
classification [16, 17]. Briefly, severe life-threatening
hemorrhage was intracerebral bleeding or resulted in
substantial hemodynamic compromise requiring treatment
(GUSTO 1). GUSTO 2 defined moderate bleeding as
the need for transfusion, whereas GUSTO 3 referred
to other bleeding, not requiring transfusion or caus-
ing hemodynamic compromise. Lastly, the number of
packs of blood products transfused was also collected.
In September 2015, a telephone interview with survi-
vors evaluated their health-related quality of life
(HRQOL), using the French version of the Medical Out-
come Study-Short Form 36-item (SF-36) questionnaire.
Its 36 items are combined to evaluate eight domains
(physical functioning, role-physical, body pain, general
health, vitality, social functioning, role-emotional, and
mental health) [18]. The aggregate physical (PCS) and
mental component summary scores (MCS) were then
computed as recommended [18]. Our patients’ mean SF-
36 levels were compared to those obtained for French
age- and sex-matched controls with no adverse condi-
tions. Anxiety and depression symptoms were assessed
with the Hospital Anxiety and Depression Scale [19],
with respective HAD-A and HAD-D subscale scores ≥8/
21 considered clinically significant [19]. Post-traumatic
stress disorder (PTSD)-related symptoms were assessed
with the Impact of Event Scale (IES) [20], with total IES
scores ≥30/75 points indicating a high risk for PTSD.
Other long-term outcome variables were: instrumental ac-
tivities of daily living (IADL) scale score [21], recurrence
of thromboembolic events, chronic dyspnea, chronic
thromboembolic pulmonary hypertension (CTEPH) diag-
nosis, persistent anticoagulant use, and return to work. To
put our massive PE ECMO-treated patients’ questionnaire
scores into perspective, we searched the literature for
other studies reporting long-term outcomes of ECMO-
treated patients, e.g., refractory septic shock [22] or acute
respiratory disease syndrome (ARDS) [23].
In accordance with the ethical standards of our hospi-
tal’s Institutional Review Board and French law, informed
consent was not necessary for analyses of demographic,
physiological, and hospital-outcome data, because this
retrospective observational study did not modify existing
diagnostic or therapeutic strategies. The National Com-
mission for Informatics and Liberties (CNIL) approved
this study (number 1950673). Survivors gave oral consent
to participate in the telephone interview conducted by the
same investigator (MS).
Literature review
We conducted a systematic MEDLINE database litera-
ture review through the PubMed search engine with a
global search strategy applying pre-specified selection
and outcome. We combined the terms “extracorporeal
life support” or “extracorporeal membrane oxygenation”
with the terms “pulmonary embolism” or “acute pul-
monary embolism” or “massive pulmonary embolism”.
See Additional file 1 for details on methodology and re-
view results.
Statistical analyses
Results are expressed as numbers (%) or median (range).
Continuous variables were compared with Student’s t
test or the Mann–Whitney U test, as appropriate,
whereas categorical variables were compared with chi-
square tests. Analyses were performed using StatView
v5.0 software (SAS Institute Inc., Cary, NC, USA) and a
two-sided p < 0.05 defined significance.
Results
Study population
During the 10-year study period, 17 patients [11 females;
median age 51 (18–70) years] received ECMO for sus-
pected (n = 2) or confirmed (n = 15) massive PE (Fig. 1).
Median SAPS II and SOFA score were high, respectively,
78 (45–95) and 12 (8–16); 11 (65%) patients had predis-
posing factors for venous thromboembolism (Table 1).
Fifteen (82%) patients suffered pre-ECMO cardiac arrest,
with seven (41%) of them cannulated during cardiopul-
monary resuscitation. Two other patients received
ECMO for refractory cardiogenic shock. Our institu-
tion’s Mobile ECMO Unit implanted peripheral fem-
oral–femoral VA-ECMO into seven (41%) patients; nine
(53%) were cannulated at beside in our department. Two
patients received ECMO for hemodynamic status deteri-
oration during surgical thrombectomy for acute pulmon-
ary embolism, including one with a RA–PA central
configuration. All patients required hemodynamic sup-
port with vasoactive drugs, resulting in a median ino-
trope score of 100 (1.8–760) μg/kg/min at ECMO
cannulation. Pre-ECMO median blood pressure, pH and
blood lactate were, respectively: 42 (0–106) mmHg, 6.99
(6.54–7.37) and 13 (4–19) mmol/L. Transthoracic or
transesophageal echocardiography visualized major RV
dilation in all patients (RV/LV dimensions ratio 1.3
[0.7–1.6]), with a proximal PA thrombus in three. Chest
CT scan confirmed PE in 12 patients of whom ten had
proximal PE. Eight patients received unsuccessful systemic
fibrinolytic therapy pre-ECMO according to standard pro-
tocols [24]. Peripheral VA-ECMO was implanted for re-
fractory cardiogenic shock several hours post-surgical
embolectomy for one patient, whereas another was
cannulated during the procedure in the operating room
(RA–PA central configuration). Two patients underwent
catheter-directed thromboaspiration: one on ECMO and
the other failed pre-ECMO because of hemodynamic in-
stability. As described in Tables 1 and 2, 24 hours on
ECMO rapidly corrected pH (6.99 [6.54–7.37] vs. 7.42
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[7.19–7.69]) and serum lactate (13.3 [4.2–19.0] vs. 3.2
[1.1–12.3] mmol/L). In addition, one patient’s follow-up
CT scans showed major clot dissolution with residual
thrombi 15 days later, including 8 days on ECMO and
prolonged heparin treatment but without systemic fibrino-
lytic therapy (see Additional file 2).
90-Day survival and hospital discharge
Table 2 reports ECMO-related complications and short-
term outcomes according to 90-day status. Almost all
patients experienced at least one major ECMO-related
complication; 15 (88%) had a moderate-to-severe
hemorrhage classified as GUSTO ≤2 with a median of 4
(0–29) packed red-cell and 5 (0–11) fresh-frozen plasma
units transfused. Eight out of 15 patients (47%) had a
SOFAliver ≥ 1 before ECMO cannulation, which was
not associated with a higher rate of severe bleeding
(p = 0.94).
Thirteen (76%) patients received renal replacement
therapy during their ICU stay. Both complications had
no impact on 90-day survival. Other complications in-
cluded: ischemic stroke in four patients, with two recov-
ering normal neurological function at hospital discharge;
arterial ischemia in two patients, one each underwent
lower limb or toe amputation, and two surgical cannula-
related, wound-infection debridement.
Nine patients died within 90 days post-ICU admission:
seven on ECMO (six of cardiac arrest-related multiorgan
failure and one of refractory cardiogenic shock despite
ECMO support), and one each after successful ECMO
weaning of secondary cardiogenic shock with multiorgan
failure or PE recurrence with sudden death 6 days post-
ECMO removal despite adequate anticoagulation. One
patient, still hospitalized 90 days post-ICU admission,
was discharged after 135 days in the hospital. It is worth
noting that only one out of the seven patients cannu-
lated while undergoing cardiopulmonary resuscitation
(CPR) was discharged alive from hospital (Fig. 1). The
eight (47%) hospital survivors, including the patient with
central ECMO, were discharged after 4 (3–11) days on
ECMO, 17 (7–91) in-ICU days and 45 (22–135) in-
hospital days. Compared with patients who died within
90 days, it is worth noting that 90-day survivors had
significantly lower inotrope scores 24 hours post-
cannulation (Fig. 2), and lower SAPS II and SOFA scores
on ECMO days 1 and 3.
Long-term outcomes
IADL, SF-36, HAD, and IES questionnaires were admin-
istered to seven of the eight long-term survivors after
median follow-up of 19 (4–74) months post-hospital dis-
charge. One patient, known to be alive at home 1 month
before follow-up, could not be reached. Daily-living ac-
tivities were normal for five patients, whereas two others
reported moderate limitations due to physical impair-
ment after lower limb or toe amputation: IADL scores of
24 and 20, respectively. Comparison with age- and sex-
matched controls highlighted limitations of all physical
domains but preserved mental health function. However,
PCS and MCS were similar to those of other ECMO-
assisted refractory septic shock and ECMO-treated
refractory ARDS patients (Fig. 3). Our respondents ex-
hibited significant anxiety (28%) or depression symptoms
(43%), or were at risk for PTSD (28%), with only two
(28%) returning to their previous work. Eighty-six
percent of long-term survivors were still taking
Fig. 1 Study flow chart. CPR cardiopulmonary resuscitation, HRQOL health- related quality of life, PE pulmonary embolism, VA-ECMO venoarterial-
extracorporeal membrane oxygenation
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anticoagulants; none reported chronic dyspnea, PE re-
currence or CTEPH diagnosis during their medical
follow-up.
Discussion
To our knowledge, this is the largest follow-up study on
VA-ECMO-treated life-threatening PE in the modern
era. Despite extreme disease severity at ECMO implant-
ation, multiorgan failure and 91% SAPS II-predicted
mortality, 47% of these patients were alive at 90 days
with acceptable long-term HRQOL. Nevertheless, after
median 19-month follow-up, physical limitations were
frequently reported, with normal mental health function.
In addition, anxiety, depression or PTSD symptoms per-
sisted for almost one-third of the survivors.
To date, literature on VA-ECMO, as rescue treatment
for extremely severe, massive PE, had been limited to
small case series or case reports with no long-term
outcome evaluation see Additional file 3 (Table 3). In
2007, Maggio et al. reported on 21 cohort patients diag-
nosed with high-risk PE between 1992 and 2005 [4]: 19
were cannulated with VA bypass, six received pre-ECMO
thrombolytic therapy and eight were cannulated after suc-
tion or surgical pulmonary embolectomy failed. Overall
survival was 62%, with catastrophic neurological events
responsible for 50% of the deaths. In our study, severe
bleeding episodes occurred in 15 (88%) patients requiring
packed red-cell and/or fresh-frozen plasma transfusions.
Major bleeding, including intracranial hemorrhage is a
well-recognized ECMO complication [25], with numerous
identified risk factors, e.g., thrombocytopenia, vasopressor
requirement, and cardiopulmonary resuscitation [25, 26].
Due to previous thrombolytic treatment and curative
anticoagulation, life-threatening PE on ECMO may carry
additional risk factors of major bleeding during this circu-
latory support.
Our results highlight that ECMO can provide lifesaving
hemodynamic support at bedside for critically ill patients
too unstable to tolerate other interventions or refractory
to other therapies. A recent survival-prediction model in-
dicated a lower predicted chance of survival for each asso-
ciated extracardiac organ failure at ECMO onset, which
starkly illustrates the crucial impact of VA-ECMO
timing for refractory cardiogenic shock [27]. To
shorten this interval, mobile ECMO teams able to im-
plant a portable and quick-to-prime ECMO circuit
just after the emergency call [28] might help clini-
cians overcome these difficulties.
Current guidelines for high-risk PE advocate using re-
perfusion therapy with systemic thrombolytic agents or
surgical pulmonary embolectomy [3]. However, those
recommendations might be questionable for the sickest
patients in severe shock or cardiac arrest, when thromb-
olysis takes time to be effective and surgery is not
Table 1 Clinical characteristics of the 17 patients at the time of
VA-ECMO implantation
Variable Value
Age, yr, median (range) 51 (18–70)
Male 6 (35)
Body mass index, kg/m2 29 (20–35)
McCabe and Jackson score ≥2 3 (18)
Charlson score ≥2 5 (29)
SAPS II 78 (45–95)
SOFA score 12 (8–16)
Predisposing factors for venous thromboembolism 11 (65)
Postoperative status 4
Immobility due to sitting 2
Oral contraception 1
Previous venous thromboembolism 3
Postpartum period 3
Hospitalization for HF or AF (within
previous 3 months)
2
ECMO implantation by Mobile ECMO Unit 7 (41)
Femoral–femoral VA-ECMO 16 (94)
Pre-ECMO cardiac arrest 15 (88)
No-flow time, min 0 (0–11)
Low-flow time, min 30 (10–85)
ECMO during cardiopulmonary resuscitation 7 (41)
Pre-ECMO systolic blood pressure, mmHg 55 (0–130)
Pre-ECMO mean blood pressure, mmHg 42 (0–106)
Pre-ECMO heart rate, bpm 95 (0–177)
Pre-ECMO inotrope score, μg/kg/min 100 (1.8–760)
pH 6.99 (6.54–7.37)
Blood lactate, mmol/L 13.3 (4.2–19.0)
Bicarbonate, mmol/L 12 (3–25)
Troponin I, μg/mL 2.2 (0.1–23.7)
PaO2/FiO2 ratio 198 (32–674)
PaCO2, mmHg 48 (17–102)
Bilirubin, mmol/L 8 (6–124)
Prothrombin activity, % 34 (10–72)
Pre-ECMO cardiac echocardiography 17 (100)
RV dilation 17 (100)
Pulmonary artery thrombus 3 (18)
LVEF, % 40 (5–60)
Pre-ECMO chest CT scan 12 (71)
Proximal PE 10 (59)
Pulmonary infarction 3 (18)
RV/LV dimensions ratio 1.3 (0.7–1.6)
Pre-ECMO systemic fibrinolytic therapy 8 (47)
Pre-ECMO surgical thrombectomy 2 (12)
Pre-ECMO catheter-directed thromboaspiration 1 (6)
Categorical variables are expressed as n (%) and continuous variables as median
(range), unless stated otherwise
VA-ECMO venoarterial-extracorporeal membrane oxygenation, SAPS II Simplified Acute
Physiology Score II, SOFA Sequential Organ Failure Assessment, AF atrial fibrillation,
HF heart failure, RV right ventricular, LVEF left ventricular ejection fraction
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immediately available. Therefore, VA-ECMO could be
used to rescue patients when thrombolytic treatments
fail or as temporary hemodynamic support prior to sur-
gical [29] or catheter-based embolectomy [30]. However,
surgical embolectomy is a major intervention requiring
sternotomy and cardiopulmonary bypass that carries sig-
nificant morbidity and mortality in this context of ad-
vanced shock and multiorgan failure; hence, VA-ECMO
might also be used alone until heparin-induced and
spontaneous endogenous thrombolysis permit weaning-
off support [5]. Herein, sufficient clot dissolution allow-
ing ECMO removal was obtained within 4 (3–11) days
for the eight patients rescued by VA-ECMO alone.
The other rationale supporting surgical thrombectomy
on ECMO is to limit the CTEPH risk [29], which has
been reported to be 0.1–9.1% for patients within the first
2 years after symptomatic PE [31]. However, data con-
firming that hypothesis are lacking. Notably, none of our
Table 2 ICU events and outcomes of ECMO-treated massive PE patients according to 90-day survival status
Event/outcome All patients (n = 17) Non-survivors (n = 9) Survivors (n = 8) p
SAPS II at ICU admission 78 (45–95) 83 (71–95) 58 (45–91) 0.04
Shock onset-to-ECMO interval, h 3 (1–24) 3 (1–24) 3.5 (1–12) 0.92
Extracorporeal blood flow during the 1st 24 h, L/min 3.3 (3.0–4.2) 3.3 (3.2–4.2) 3.2 (3.0–3.9) 0.19
SOFA score at ECMO cannulation 12 (8–19) 15 (11–19) 12 (8–15) 0.11
Inotrope score at ECMO cannulation, μg/kg/min 100 (2–760) 75 (2–730) 143 (92–760) 0.17
Inotrope score after 24 h of ECMO, μg/kg/min 50 (0–660) 75 (41–660) 6 (0–51) 0.001
pH ECMO-day 1 7.42 (7.19–7.69) 7.40 (7.19–7.57)a 7.44 (7.32–7.69) 0.79
Blood lactate ECMO-day 1, mmol/L 3.2 (1.1–12.3) 4.5 (1.1–12.3)a 2.3 (1.1–3.5) 0.17
SOFA score
ECMO-day 1 14 (11–18) 14 (13–18) 12 (11–16) 0.04
ECMO-day 3 13 (8–18) 15 (12–18) 13 (8–15) 0.03
ECMO-day 7 6 (1–19) 10 (7–13) 6 (1–19) 0.29
In-ICU complications
Hemorrhage≤ GUSTO 2 15 (88) 8 (89) 7 (88) 0.92
RRT 13 (76) 6 (67) 7 (88) 0.31
Stroke 4 (24) 1 (11) 3 (38) 0.2
Surgical wound infection 2 (12) 0 2 (25) –
Arterial ischemia 1 (6) 0 1 (12) –
Packed red-cell units transfused 4 (0–29) 4 (0–6) 9 (0–29) 0.7
Fresh-frozen plasma units transfused 5 (0–11) 3 (0–8) 8 (0–11) 0.7
Tracheotomy 2 (12) 0 2 (25) –
ECMO duration, days 4 (1–12) 3 (1–13) 4 (3–11) 0.28
MV duration, days 10 (1–43) 3 (1–24) 13 (1–43) 0.03
ICU LOS, days 10 (1–91) 3 (1–24) 17 (7–91) 0.009
Hospital LOS, days 22 (1–135) 6 (1–36) 45 (22–135) 0.004
Categorical variables are expressed as n (%) and continuous variables as median (range)
ICU intensive care unit, ECMO extracorporeal membrane oxygenation, PE pulmonary embolism, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure
Assessment, GUSTO Global Utilization of Streptokinase and TPA for Occluded arteries, RRT renal replacement therapy, MV mechanical ventilation, LOS length of stay
aThree patients died within less than 24 h on ECMO
Fig. 2 Box plots of the inotrope score change between pre- and
post-VA-ECMO cannulation according to patients’ 90-day status. Bold
horizontal lines are medians; lower and upper box limits are 25th–75th
percentiles; T-bars represent 10th–90th percentiles. ECMO extracorporeal
membrane oxygenation
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long-term survivors developed CTEPH. In addition, des-
pite significant mechanical PA obstruction by massive
PE, thrombectomy to prevent CTEPH is not yet system-
atically advocated [3]. The lack of linear correspondence
between the degree of mechanical obstruction and
CTEPH risk, because of concomitant small-vessel pul-
monary arteriopathy [32], makes the benefit of adding
surgical thrombectomy in this context questionable.
Lastly, a recent systematic review of case reports and
case series published over the past 20 years found simi-
lar outcomes for patients who underwent surgical or
catheter embolectomy or no additional therapies on
ECMO [7]. The benefit of mechanical removal therapies,
e.g., catheter or surgical thrombectomy, over exclusive
VA-ECMO use warrants further investigation.
Despite very severe disease at ECMO initiation, the
47% 90-day survival observed for our series is comparable
with results reported in studies included in our systematic
review (Table 3) and with the 42% hospital-survival rate of
a large international cohort of ECMO-treated refractory
cardiogenic shock patients [27]. Despite high numbers of
our patients with pre-ECMO cardiac arrest or cannulated
during cardiopulmonary resuscitation, our survivors’ sur-
vival rate was also higher than those reported for ECMO-
treated in- and out-of-hospital cardiac arrest (28.8% and
4%, respectively) [33, 34]. However, HRQOL evaluated
after median 19-month follow-up, was still impaired, com-
pared to sex- and age-matched controls, especially con-
cerning SF-36 physical health and social-functioning
domains, while general and mental health were considered
satisfactory. Although, case-mix differences make compar-
isons between series difficult, we observed than our ex-
tremely ill patients’ SF-36 scores were similar to those of
both ECMO-assisted refractory shock [22] and ECMO-
treated refractory ARDS patients [23]. Nevertheless,
the burden of ECMO-induced physical limitations for
our ECMO-treated survivors was still perceptible
19 months post-hospital discharge with back-to-work
impact. Although thoroughly described in previous
case series [8–10], ECMO-related long-term physical
sequelae have not been investigated. Future studies
are warranted to prevent these complications and im-
prove their long-term management.
Our study’s strengths are the larger number of consecu-
tive patients included and their detailed characterization,
and its longitudinal design with median survivor follow-
up 19 months post-ICU discharge. However, our study
also has limitations. First, it is a retrospective, single-
center study. Second, the self-assessed persistently im-
paired physical health and vitality might not be specific to
PE but may represent sequelae of any severe disease re-
quiring prolonged ICU stay and ECMO, including critical
Fig. 3 Comparison of median Short Form-36 scores of our high-risk massive PE survivors treated with VA-ECMO after median 19-month follow-up
post-hospital discharge and their age- and sex-matched control subjects [18], 67 venovenous-ECMO-treated acute respiratory distress syndrome
(ARDS) survivors at 17-month follow-up [23] and ten VA-ECMO-treated septic shock patients [23]. Higher scores denote better health-related quality of
life. ECMO extracorporeal membrane oxygenation, ARDS acute respiratory disease syndrome, PF physical functioning, RP role-physical, BP body pain,
GH general health, VT vitality, SF social functioning, RE role-emotional, MH mental health, PCS physical component score, MCS mental component score
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illness, muscle wasting, and weakness. Third, we did not
perform protocolized follow-up based on long-term car-
diac echocardiography and imaging to detect CTEPH de-
velopment. Further studies focusing on this point are
needed to support long-term safety of an ECMO strategy
without additional mechanical clot-removal therapies.
Lastly, PE diagnosis was confirmed in 15 out of the 17 pa-
tients. The remaining two patients had high massive PE
suspicion but died within 24 hours after ICU admission
without chest CT scan performed. The family refused aut-
opsy. However, they both had prolonged cardiac arrest
with massive RV dilatation on cardiac echocardiography,
predisposing factors for venous thromboembolism, and
no evidence of right myocardial infarction.
Conclusions
In conclusion, long-term survival of our 17 VA-ECMO–
treated patients with life-threatening, massive PE
reached 47%. Although only limited data support VA-
ECMO effectiveness in this context at present, our re-
sults suggest that it could be a lifesaving rescue therapy
to rapidly restore hemodynamic status when thrombo-
lytic therapy fails or when the patient is deemed too sick
to benefit from medical or surgical treatments. Consid-
ering that heparin-induced clot dissolution and spontan-
eous fibrinolysis allows ECMO weaning after only a few
days on support, the benefit of additional mechanical
clot-removal therapies, e.g., catheter-based or surgical
thrombectomy on ECMO, also warrant investigation.
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surgical pulmonary
embolectomies
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